January 25, 2019 / 2:17 PM / 10 months ago

BUZZ-Aptose Biosciences: Rises as Oppenheimer starts with outperform rating

** U.S.-listed shares of Canadian drug developer rise 13.9 pct to $2.3 premarket

** Brokerage Oppenheimer initiates APTO coverage with outperform rating (PT $6), citing commercial potential of co’s clinical-stage cancer drug CG-806 in two major indications - acute myeloid leukemia and chronic lymphocytic leukemia

** Oppenheimer considers CG-806 as two potent drugs rolled into one

** All 4 brokerages covering the co rate the stock “buy” or higher; median PT is $6.5 vs $8.5 in Oct 2018

** APTO had slumped 14.7 pct in 2018 (Reporting by Manogna Maddipatla)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below